Supplementary Figure 9. Risk of recurrence based on ctDNA detection early on adjuvant chemotherapy in patients with stage II or higher CRC.
No takes yet. Share an insight, caveat, or question.
Nakamura et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: